...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta ophthalmologica >Effect of intravitreal bevacizumab (Avastin?) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results
【24h】

Effect of intravitreal bevacizumab (Avastin?) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results

机译：使用基于光学相干断层扫描的治疗方案，玻璃体内贝伐单抗（Avastin？）在新生血管性年龄相关性黄斑变性中的作用：6个月和12个月结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To study the effect of intravitreal bevacizumab therapy on visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) within a follow-up period of 6 and 12 months. Methods: A retrospective analysis of 102 eyes of 102 consecutive patients with neovascular AMD evaluated repeated intravitreal bevacizumab (1 or 2.5 mg) injections. Retreatment was performed following an optical coherence tomography (OCT)-based regimen. Ophthalmic examination included best-corrected visual acuity (BCVA), dilated fundus examination and OCT imaging. Data were analysed at baseline, 6 months (24 weeks) and 12 months (48 weeks) after treatment initiation. Results: BCVA remained stable at 6 months (mean: 0.00 ± 0.41 logMAR; p = 0.95) and 12 months (mean: +0.02 ± 0.43 logMAR; loss of ～ 1 letter; p = 0.70) after the first treatment. OCT retinal thickness decreased by a mean of -37.8 ± 101.6 μm (p < 0.05) compared to baseline at month 6 and -38.6 ± 93.3 μm (p < 0.05) at month 12. A mean of 2.6 ± 1.2 injections were needed to obtain absence of fluid by OCT, and the time to recurrence was 23 ± 11 weeks thereafter. There was no difference in BCVA and OCT outcomes between treatment-naive eyes and eyes that had undergone prior treatment. Conclusion: The 6- and 12-month follow-up of repeated intravitreal bevacizumab therapy in eyes with neovascular AMD demonstrated stabilization of vision and no safety concerns. An OCT-based retreatment strategy appears appropriate in the management of patients treated with intravitreal bevacizumab.
机译：目的：研究玻璃体内贝伐单抗治疗对新生血管性年龄相关性黄斑变性（AMD）患者的视觉和解剖结局的影响，为期6个月和12个月。方法：回顾性分析连续血管新生血管性AMD患者102眼102眼，评估了玻璃体内贝伐单抗（1或2.5 mg）的重复注射。在基于光学相干断层扫描（OCT）的治疗方案后进行了重新治疗。眼科检查包括最佳矫正视力（BCVA），扩大眼底检查和OCT成像。在治疗开始后的基线，6个月（24周）和12个月（48周）对数据进行分析。结果：第一次治疗后，BCVA在第6个月（平均：0.00±0.41 logMAR; p = 0.95）和12个月（平均：+0.02±0.43 logMAR;丢失〜1个字母; p = 0.70）保持稳定。与第6个月的基线相比，OCT视网膜厚度平均降低了-37.8±101.6μm（p <0.05），而在第12个月时则降低了-38.6±93.3μm（p <0.05）。需要平均注入2.6±1.2 OCT提示没有液体，此后复发时间为23±11周。初次治疗的眼睛和先前接受过治疗的眼睛之间的BCVA和OCT结果没有差异。结论：对新生血管性AMD眼睛进行玻璃体内贝伐单抗重复治疗的6个月和12个月随访表明，视力稳定且无安全隐患。基于OCT的再治疗策略似乎适用于玻璃体内贝伐单抗治疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号